Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: A case of highly variable rate of drug absorption

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 9, 2010, Pages 621-627

  Estevez Carrizo, F E ^a   Parrillo, S ^a   Cedres, M ^b   Estevez Parrillo, F T ^b   Rodriguez, P ^b  

^a UNIVERSIDAD DE MONTEVIDEO   (Uruguay)

^b Hospital Italiano Montevideo   (Uruguay)

Author keywords

Absorption rate; Bioequivalence; Immunosuppressant; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; SUPRIMUN; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; URUGUAY; VITAL SIGN; VOLUNTEER; ABSORPTION; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; URUGUAY;

EID: 77956899783     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48621     Document Type: Article

References (18)

1. Bullingham R, Nicholls AJ, Kamm BR. Clinical Pharmacokinetics of Mycophenolate Mofetil. Clin Pharmacokinet. 1998; 6: 429-455.
2. Diletti E, Hauschke D, Steinijans W. Sample size determination: Extended tables for the multiplicative model and bioequivalence ranges of 09 to 1.11 and 0.70 to 1.43. Int J Clin Pharmacol, Ther Toxicol. 1992; 30 (Suppl): 59-62.
3. Elbarbry FA, Shoker A. Simple high performance liquid chromatographic assay for mycophenolic acid in renal transplant patients. J Pharm Biomed Anal. 2007; 43: 788-792.
4. max for absorption rates in investigation of bioequivalence. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 394-399.
5. max/ AUC in investigation of bioequivalence. Int J Clin Pharmacol Ther Toxicol.1993; 31: 184-189.
6. Hauschke D, Steinijans V, Pigeot I. Bioquivalence Studies in Drug Development. Chapter 2: "Metric to characterize concentration-time profile in single-and multiple-dose bioequivalence studies." West Sussex: John Wiley & Sons, Ltd.; 2007.
7. Lacey LF, Keene ON, Duquesnoy C, Bye A. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharmaceutic Scie. 1984; 83: 212-215.
8. Manzia TM, De Liguori N, Orlando G, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc. 2005; 37: 2616-2617.
9. Marzo A, Balant LP. Bioequivalence: An updated reappraisal addressed to application of interchangeable multi-source pharmaceutical products. Arzneimittelforschung. 1995; 45: 109-115.
10. Pan American Network on Drug Regulatory Harmonization (PANDRH)-Pan American Health Organization (PAHO). Working Group on Bioequivalence. 2008.
11. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995; 17: 681-684.
12. Sauter R, Steinijans VW, Diletti E, Bohm A, Schulz H-U. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992; 30 (Suppl): 7-30.
13. Schall R, Luus HG, Steinijans VW, Hauschke D. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations. Int J Clin Pharmacol Ther. 1994; 32: 323-328.
14. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
15. Schulz HU, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol, Ther Toxicol. 1992; 30 (Suppl.): 1-6.
16. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Ablinded, randomized clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029-1037.
17. Tozer TN, Bois FY, Hauck WW, Chen ML, Williams RL. Absorption rate vs. exposure: which is more useful for bioequivalent testing? Pharm Res. 1996; 13: 453-456.
18. World Health Organization. Addditional Guidance for Organizations Performing in vivo Bioequivalence Studies. Working document QAS/05.120/ Rev. 1. Geneva: WHO; 2005.